Graded effects of proteinuria on HDL structure in nephrotic rats

Journal of the American Society of Nephrology

Volumn 16, Issue 5, 2005, Pages 1309-1319

  Shearer, Gregory C ^a   Newman, John W ^b   Hammock, Bruce D ^b   Kaysen, George A ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHYLOMICRON; DOXORUBICIN; SERUM ALBUMIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTINEOPLASTIC ANTIBIOTIC; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; HEYMANN NEPHRITIS; HYPOALBUMINEMIA; LIQUID CHROMATOGRAPHY; NEPHROTIC SYNDROME; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEINURIA; RAT; TIME OF FLIGHT MASS SPECTROMETRY; ALBUMINURIA; ANIMAL; CHEMICALLY INDUCED DISORDER; ELECTROSPRAY MASS SPECTROMETRY; GLOMERULONEPHRITIS; METABOLISM; NEPHROSIS; SPRAGUE DAWLEY RAT;

ALBUMINURIA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; CHOLESTEROL, HDL; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLOMERULONEPHRITIS; NEPHROSIS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 23944509838     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004080644     Document Type: Article

References (55)

1. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53: 994-1001, 1998
2. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40: 129 138, 1991
3. Shearer GC, Stevenson FT, Atkinson DN, Staprans I, Kaysen GA: Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney M 59: 179-189, 2001
4. Kaysen GA, Mehendru L, Pan XM, Staprans I: Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 263: F335-F341, 1992
5. de Sain-van der Velden MG, Rabelink TJ, Gadellaa MM, Elzinga H, Reijngoud DJ, Kuipers F, Stellaard F: In vivo determination of very-low-density lipoprotein-apolipoprotein B100 secretion rates in humans with a low dose of 1-[1-13C]valine and isotope ratio mass spectrometry. Anal Biochem 265: 308-312, 1998
6. Shearer GC, Couser WG, Kaysen GA: Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL. Kidney Int 65: 228-237, 2004
7. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418, 1997
8. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736-741, 1992
9. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Deferrari G, Pontremoli R: Microalbuminuria identifies overall cardiovascular risk in essential hypertension: An artificial neural network-based approach. J Hypertens 20: 1315-1321, 2002
10. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 2: 530-533, 1988
11. Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 16: 952-958, 2003
12. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM: Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 13: 1626-1634, 2002
13. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; DCCT/EDIC Research Group: Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int 64: 817-828, 2003
14. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J: Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48: 2533-2540, 2003
15. Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, Achenbach S, Manger B: Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62: 846-850, 2003
16. Kessler MA, Meinitzerv A, Petek W, Wolfbeis OS: Microalbuminuria and borderline-increased albumin excretion determined with a centrifugal analyzer and the Albumin Blue 580 fluorescence assay. Clin Chem 43: 996-1002, 1997
17. Kessler MA, Meinitzer A, Wolfbeis OS: Albumin blue 580 fluorescence assay for albumin. Anal Biochem 248: 180-182, 1997
18. Schumaker VN, Puppione DL: Sequential flotation ultracentrifugation. Methods Enzymol 128: 155-170, 1986
19. Edelstein C, Scanu AM: Precautionary measures for collecting blood destined for lipoprotein isolation. Methods Enzymol 128: 151-155, 1986
20. Shearer GC, Couser WG, Kaysen GA: Endothelial chylomicron binding is altered by interaction with high-density lipoprotein in Heymann's nephritis. Am J Kidney Dis 38: 1385-1389, 2001
21. Andersson Y, Thelander L, Bengtsson-Olivecrona G: Demonstration of apolipoprotein CII in guinea pigs. Functional characteristics, cDNA sequence, and tissue expression. J Biol Chem 266: 4074-4080, 1991
22. Sparks CE, Tennenberg SD, Marsh JB: Related catabolism of the apolipoproteins of HDL in control and nephrotic rats. Biochim Biophys Acta 665: 8-12, 1981
23. Sun X, Martin V, Weiss RH, Kaysen GA: Selective transcriptional augmentation of hepatic gene expression in the rat with Heymann nephritis. Am J Physiol 264: F441-F447, 1993
24. Marshall JF, Apostolopoulos JJ, Brack CM, Howlett GL: Regulation of apolipoprotein gene expression and plasma high-density lipoprotein composition in experimental nephrosis. Biochim Biophys Acta 1042: 271-279, 1990
25. Kaysen GA, Hoye E, Jones H Jr, van Tol A, Joles JA: Effect of oncotic pressure on apolipoprotein A-I metabolism in the rat. Am J Kidney Dis 26: 178-186, 1995
26. Labeur C, Lambert G, Van Cauteren T, Duverger N, Vanloo B, Chambaz J, Vandekerckhove J, Castro G, Rosseneu M: Displacement of apo A-I from HDL by apo A-II or its C-terminal helix promotes the formation of pre-beta1 migrating particles and decreases LCAT activation. Atherosclerosis 139: 351-362, 1998
27. Short CD, Durrington PN, Mallick NP, Hunt LP, Tetlow L, Ishola M: Serum and urinary high density lipoproteins in glomerular disease with proteinuria. Kidney Int 29: 1224-1228, 1986
28. Vincent C, Revillard JP, Traeger J: Alteration of beta2-microglobulin metabolism in terminal chronic renal insufficiency. Pathol Biol (Paris) 26: 303-306, 1978
29. DeLamatre JG, Hoffmeier CA, Lacko AG, Roheim PS: Distribution of apolipoprotein A-IV between the lipoprotein and the lipoprotein-free fractions of rat plasma: Possible role of lecithin:cholesterol acyltransferase. J Lipid Res 24: 1578-1585, 1983
30. van Goor H, van der Horst ML, Atmosoerodjo J, Joles JA, van Tol A, Grond J: Renal apolipoproteins in nephrotic rats. Am J Pathol 142: 1804-1812, 1993
31. Steinmetz A, Utermann G: Activation of lecithin:cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem 260: 2258-2264, 1985
32. Guyard-Dangremont V, Lagrost L, Gambert P: Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. J Lipid Res 35: 982-992, 1994
33. Warner MM, Guo J, Zhao Y: The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl) 114: 275-279, 2001
34. Verges BL, Lagrost L, Vaillant G, Petit JM, Cohen M, Gambert P, Brun JM: Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM. Diabetes 46: 125-132, 1997
35. Ostos MA, Concord M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM: Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21: 1023-1028, 2001
36. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, Najib J, Fruchart JC, Miller NE, Zakin MM, Ochoa A: Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arteriosder Thromb Vasc Biol 20: 2267-2274, 2000
37. Vaziri ND, Liang K, Parks JS: Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 280: F823-F828, 2001
38. Lima VL, Harry DS, McIntyre N, Owen JS, Chaves ME: Characterization and potential uses of rabbit polyclonal antibodies against human plasma lecithin-cholesterol acyltransferase. Braz J Med Biol Res 29: 957-968, 1996
39. Wang J, Gebre AK, Anderson RA, Parks JS: Short sequence-paper: Cloning and in vitro expression of rat lecithin:cholesterol acyltransferase. Biochim Biophys Acta 1346: 207-211, 1997
40. Adimoolam S, Jin L, Grabbe E, Shieh JJ, Jonas A: Structural and functional properties of two mutants of lecithin-cholesterol acyltransferase (T123I and N228K). J Biol Chem 273: 32561-32567, 1998
41. Jin L, Shieh JJ, Grabbe E, Adimoolam S, Durbin D, Jonas A: Surface plasmon resonance biosensor studies of human wild-type and mutant lecithin cholesterol acyltransferase interactions with lipoproteins. Biochemistry 38: 15659-15665, 1999
42. de Beer MC, Castellani LW, Cai L, Stromberg AJ, de Beer FC, van der Westhuyzen DR: ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36. J Lipid Res 45: 706-715, 2004
43. Durbin DM, Jonas A: The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem 272: 31333-31339, 1997
44. Durbin DM, Jonas A: Lipid-free apolipoproteins A-I and A-II promote remodeling of reconstituted high density lipoproteins and alter their reactivity with lecithin:cholesterol acyltransferase. J Lipid Res 40: 2293-2302, 1999
45. Lagrost L, Persegol L, Lallemant C, Gambert P: Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and All. J Biol Chem 269: 3189-3197, 1994
46. Hime NJ, Barter PJ, Rye KA: The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 273: 27191-27198, 1998
47. Brown WV, Baginsky ML: Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46: 375-382, 1972
48. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P: Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 25: 258-262, 1999
49. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC: Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 15: 963-971, 1995
50. Gerber Y, Goldbourt U, Feinberg MS, Segev S, Harats D: Are triglyceride-rich lipoproteins associated with aortic valve sclerosis? A preliminary report. Atherosclerosis 170: 301-305, 2003
51. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R: Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44: 2374-2381, 2003
52. Hirano T, Ebara T, Furukawa S, Nagano S, Takahashi T: Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metabolism 43: 248-256, 1994
53. Yokoyama H, Aoki T, Imahori M, Kuramitsu M: Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intimamedia thickness and pulse wave velocity. Kidney Int 66: 448-454, 2004
54. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ: Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: The EPIC-Norfolk population-based study. Eur J Cardiovasc Prev Rehabil 11: 207-213, 2004
55. Pedrinelli R, Dell'Omo G, Penno G, Bandinelli S, Bertini A, Di Bello V, Mariani M: Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 35: 48-54, 2000